IndiviorNASDAQ: INDV

Indivior PLC (INDV) reported quarterly earnings of $0.37 per share, falling short of the Zacks Consensus Estimate of $0.38 per share. This is lower than the earnings of $0.40 per share from the same period last year.

Indivior PLC, a pharmaceuticals company listed in London, has officially announced its plans to shift its main listing to the United States, as expected. Shareholders will still need to vote on the move, but it is likely to be approved easily due to the backing of major shareholders.

Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Indivior PLC (LSE:INDV), the pharma firm developing medicines to treat addiction and mental illnesses, has edged closer to a move to the US after a top-ten shareholder said it would back the move. Last month, the group said it would be considering switching its primary listing on the London Stock Exchange for the Nasdaq, but would consult shareholders beforehand.

Indivior PLC (INDV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Invest in companies like Modine Manufacturing (MOD), Indivior (INDV) and Interface (TILE) that are powered by higher efficiency levels.

Indivior PLC (LSE:INDV)'s shares surged 16% in early trading as the drugmaker announced plans to relocate its primary listing from London to New York, seeking to enhance its appeal to US investors as well as aiming for inclusion in major stock indices. The company, known for its opioid use disorder and schizophrenia treatments, revealed this strategic move alongside its full-year results, stating the listing shift could occur in the summer of 2024, pending shareholder approval.

UK-listed drugmaker Indivior Plc has begun consulting shareholders on shifting its primary listing to the United States by the middle of this year, it said on Thursday, after reporting a 27% jump in annual profit.

Indivior PLC (LSE:INDV), a company specialising in addiction treatment, has settled a legal dispute with Actavis, a part of Teva Pharmaceuticals. The disagreement was about Actavis's plan to make a generic version of a drug combining buprenorphine and a naloxone sublingual film.